PhRMA and Arkansas Seek Faster Court Ruling on State’s Novel 340B Contract Pharmacy Law

PhRMA and the state of Arkansas have agreed on a plan that could lead the federal district court in Little Rock to rule sooner than now anticipated on the state’s law protecting 340B contract pharmacy arrangements.

The brand name drug industry and the state of Arkansas have agreed on a litigation plan that could lead to a quicker federal court decision than now anticipated on the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.

Read More »

AHA Asks Congress to Attach 340B Hospital Protections to Must-Pass Spending Bill

The AHA asked congressional leaders yesterday to ensure that a must-pass spending bill next month protects hospitals from losing their 340B eligibility due to changes forced on them by the COVID-19 pandemic.

The American Hospital Association (AHA) yesterday asked U.S. House and Senate party leaders to ensure that a must-pass spending bill next month protects hospitals from losing their 340B eligibility due to changes in patient and payer mix caused by the

Read More »

Ready to Future Proof Your Business? The Time to Act Is Now.

SPONSORED CONTENT

Drastic federal cuts to the 340B program. Alarming changes to Gilead’s Advancing Access Program. If your organization is a federal grantee or health system providing HIV care and/or prevention services, you know there has never been a more important time to future-proof your program—while still offering the highest standards of compassionate care.

What’s more, how entities provide care to their communities is

Read More »

Three Drug Makers, Including Two with Contract Pharmacy Restrictions, Post 340B Refund Notices

Bristol Myers Squibb, Novo Nordisk, and Ipsen Biopharmaceuticals notified 340B covered entities this week about refunds for charges above 340B ceiling prices.

Three drug manufacturers—including two that have imposed conditions on 340B contract pharmacy—posted public notices this week to 340B covered entities about refunds for charges above 340B ceiling prices.

Please Login or Become a Paid Subscriber to

Read More »

Democrats Weigh Passing Build Back Better Act—Possibly Including Drug Pricing Reforms—in “Chunks”

New CBO findings on brand drug price increases “drive home the urgent need to pass robust drug pricing reforms," U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week.

U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week that new Congressional Budget Office (CBO) findings on brand drug price increases “drives home the urgent need to pass robust drug pricing reforms.”

Please Login

Read More »

View from Capitol Hill Breakfast: Get the Latest Developments in the Ever-Changing 340B Program

SPONSORED CONTENT

Are you attending the upcoming 340B Coalition Winter Conference in San Diego? Join us for breakfast!

Marriott Marquis San Diego Marina

Monday, January 31 | 8:30 a.m. PT

Omnicell 340B will be hosting a panel discussion with some of the most respected long-term experts on the 340B program at the upcoming 340B Coalition

Read More »

Groups and Individual Health Care Providers Grapple with BMS’s New 340B Contract Pharmacy Policy

Individual 340B covered entities are deciding how to respond to the multi-point 340B contract pharmacy policy that Bristol Myers Squibb (BMS) released last Friday.

Groups that represent 340B hospitals yesterday slammed the multi-point 340B contract pharmacy policy that Bristol Meyers Squibb (BMS) released last Friday.

Please Login or Become a Paid Subscriber to View this Content

Read More »

With Judge in Astra 340B Case About to Get Promotion, What Will Happen to the Highly Anticipated Case?

The U.S. Senate could elevate Leonard Stark, the federal judge who has presided over AstraZeneca’s 340B contract pharmacy lawsuit, to a federal appeals court as soon as the end of this week.

Leonard Stark, the federal judge who presided over AstraZeneca’s 340B contract pharmacy lawsuit from its start last year, is on the verge of being elevated to a higher court, possibly by the end of this week. If that happens before

Read More »

“Pharma Bro” Who Drew Ire of 340B Providers and Drug Industry Alike Barred from Pharmaceutical Industry for Life

A federal district judge imposed a lifetime ban against Martin Shkreli participating in the pharmaceutical industry and ordered him to pay $64.6 million to offset ill-gotten gains, stemming from his company's purchase of and huge price hike on the drug Daraprim.

A federal district judge on Friday held “pharma bro” Martin Shkreli liable for antitrust claims brought by the Federal Trade Commission (FTC) and seven states.

Please Login or Become a Paid Subscriber to View this Content

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report